A paradigm shift has occurred in the management of non-small-cell lung cancer (NSCLC) due to advances in cancer immunotherapy, including immune checkpoint inhibitors (ICIs) that target programmed cell death-1 (PD-1) and programmed cell death-ligand 1 (PD-L1) (1, 2). This evidence concerns the gene CD274 and non-small cell lung carcinoma.